A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
At a glance
- Drugs AGS 16C3F (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; First in man; Pharmacokinetics
- 30 May 2018 Results of two phase1 trial (NCT01114230 and NCT01672775), were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 14 May 2015 Results will be presented at ASCO Annual Meeting 2015, per Astellas Pharma media release.